Onxeo’s Shares Transferred to Compartment B on Euronext Paris

PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE)-- Regulatory News :

Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO) (Euronext Paris, NASDAQ OMX
Copenhagen: ONXEO), an innovative company specializing in the development of
orphan oncology drugs, today announces that its shares will be transferred from
Compartment C to Compartment B of the NYSE Euronext Paris with effect from
January 28, 2015.

According to the regulations of NYSE Euronext, compartment changes are made
annually on the basis of the market capitalization of the last 60 trading days
of the year. Compartment B consists of listed companies with a market
capitalization of between €150 million and €1 billion.

The transfer comes a few weeks after the selection of Onxeo to enter the
EnterNext© PEA-PME 150, a benchmark index launched in November 2014 in response
to the industry’s demand for new benchmarks.

“The transfer of our shares to Compartment B is a key event showing the
progression of our market value. After a successful merger in 2014, Onxeo now
relies on strong fundamentals: 3 products in an advanced clinical stage, all
positioned on dynamic markets in the orphan oncology field, and on an
experienced team who already registered 3 products in the US and Europe, today
commercialized by our partners. The company has also strengthened its own funds
with a significant capital increase in December 2014. These assets and our
reinforced market visibility should increase our attractivity to international
investors in the next months”, comments Nicolas Fellmann, CFO of Onxeo.

About Onxeo
Onxeo has the vision to become a global leader and pioneer in oncology, with a
focus on orphan or rare cancers, through developing innovative therapeutic
alternatives to “make the difference”. The Onxeo teams are determined to develop
innovative medicines to provide patients with hope and significantly improve
their lives.

Key products at advanced development stage are:
Livatag® (Doxorubicin Transdrug™): Phase III in hepatocellular carcinoma
Validive® (Clonidine Lauriad®): Phase II in severe oral mucositis: Positive
preliminary top-line results
Beleodaq® (belinostat): registered in the US in peripheral T-cell lymphoma
For more information, visit the website www.onxeo.com

Disclaimer

This communication expressly or implicitly contains certain forward-looking
statements concerning Onxeo and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors, which could cause the
actual results, financial condition, performance or achievements of Onxeo to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Onxeo is providing this
communication as of this date and does not undertake to update any forward
-looking statements contained herein as a result of new information, future
events or otherwise. For a discussion of risks and uncertainties which could
cause actual results, financial condition, performance or achievements of Onxeo
to differ from those contained in the forward-looking statements, please refer
to the Risk Factors ("Facteurs de Risque") section of the 2013 Reference
Document filed with the AMF on April 7, 2014, which is available on the AMF
website (http://www.amf-france.org) or on the company’s website (www.onxeo.com).
Onxeo
Judith Greciet, CEO
j.greciet@onxeo.com
or
Nicolas Fellmann, CFO
n.fellmann@onxeo.com
+33 1 45 58 76 00
or
Alize RP
Caroline Carmagnol / Sophie Colin , +33 6 64 18 99 59 / +33 1 44 54 36 62
caroline@alizerp.com / scolin@alizerp.com